Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Natural killer (NK) cells possess cytotoxic activity against cancer cells that downregulate HLA class I molecules, evading T cell recognition.
• This unique recognition mechanism offers a strategy to overcome immune tolerance in cancer and leukemia patients.
• NK cell-mediated anti-leukemia effects are significant, particularly in haploidentical stem cell transplantation.

Purpose of the Study:

• To review the historical significance of NK cells in cancer therapy.
• To explore recent advancements in enhancing NK cell functions for treating hematological malignancies.
• To discuss novel therapeutic approaches involving NK cells.

Main Methods:

• Review of existing literature on NK cell biology and cancer immunotherapy.
• Analysis of methods for ex vivo expansion of NK cells (autologous and allogeneic).
• Examination of emerging strategies such as checkpoint receptor blockade, memory-like NK cells, and chimeric antigen receptor (CAR)-NK cells.

Main Results:

• NK cells provide a valuable therapeutic avenue for cancers evading T cell immunity.
• Ex vivo expansion techniques allow for the generation of sufficient NK cells for adoptive immunotherapy.
• Novel approaches like CAR-NK cells and checkpoint blockade show potential for improved anti-cancer efficacy.

Conclusions:

• NK cells represent a critical component of the innate immune system with significant anti-cancer potential.
• Therapeutic strategies aimed at enhancing NK cell activity are advancing the treatment of hematological malignancies.
• Future research directions include optimizing NK cell expansion and engineering for broader clinical application.